Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.
   PubMed Web of Science ®Google Scholar
• Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370:1464–1468.
   PubMed Web of Science ®Google Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021. doi:https://doi.org/10.1038/s41586-021-03398-2
   Google Scholar
• Shen X, Tang H, Pajon R, et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. N Engl J Med. 2021. doi:https://doi.org/10.1056/NEJMc2103740
   Google Scholar
• Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021. doi:https://doi.org/10.1038/s41591-021-01318-5
   Google Scholar
• Wang GL, Wang ZY, Duan LJ, et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N Engl J Med. 2021. doi:https://doi.org/10.1056/NEJMc2103022
   Google Scholar
• Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184:2362–2371.
   PubMed Web of Science ®Google Scholar
• Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021. doi:https://doi.org/10.1126/science.abh2644
   Web of Science ®Google Scholar
• Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021. doi:https://doi.org/10.1016/j.cell.2021.03.055
   Google Scholar
• West AP, Wertheim JO, Wang JC, et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. bioRxiv. 2021. doi:https://doi.org/10.1101/2021.02.14.431043
   Google Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361–370.
   PubMed Web of Science ®Google Scholar
• Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases – borrowing from history. N Engl J Med. 2018;378:1469–1472.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020. doi:https://doi.org/10.1126/science.abc6952
   Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–124.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456.
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010–1014.
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115–119.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956–963.
   PubMed Web of Science ®Google Scholar
• Alsoussi WB, Turner JS, Case JB, et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J Immunol. 2020;205:915–922.
   PubMed Web of Science ®Google Scholar
• Dong J, Huang B, Jia Z, et al. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. Emerg Microbes Infect. 2020;9:1034–1036.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab; 2021. https://www.fda.gov/media/145802/download
   Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2029849
   Web of Science ®Google Scholar
• Chen Y, Vaine M, Wallace A, et al. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol. 2013;87:10232–10243.
   PubMed Web of Science ®Google Scholar
• Starkie DO, Compson JE, Rapecki S, et al. Generation of recombinant monoclonal antibodies from immunised mice and rabbits via flow cytometry and sorting of antigen-specific IgG+ memory B cells. PLoS One. 2016;11:e0152282.
   PubMed Web of Science ®Google Scholar
• Seeber S, Ros F, Thorey I, et al. A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood. PLoS One. 2014;9:e86184.
   PubMed Web of Science ®Google Scholar
• Cheung WC, Beausoleil SA, Zhang X, et al. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat Biotechnol. 2012;30:447–452.
   Web of Science ®Google Scholar
• Markham A. Brolucizumab: first approval. Drugs. 2019;79:1997–2000.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Powell R, Yahyaei S, et al. Rationally designed vaccines targeting the V2 region of HIV-1 gp120 induce a focused, cross-clade-reactive, biologically functional antibody response. J Virol. 2016;90:10993–11006.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang S, Lu S. DNA immunization for HIV vaccine development. Vaccines. 2014;2:138–159.
   PubMedGoogle Scholar
• Houser KV, Yamshchikov GV, Bellamy AR, et al. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS One. 2018;13:e0206837.
   PubMed Web of Science ®Google Scholar
• Joyce MG, Wheatley AK, Thomas PV, et al. Vaccine-induced antibodies that neutralize Group 1 and Group 2 influenza A viruses. Cell. 2016;166:609–623.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhou F, Buchy P, et al. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin. J Infect Dis. 2014;209:676–685.
   Web of Science ®Google Scholar
• Obaldia N, Stockelman MG, Otero W, et al.. A plasmodium vivax plasmid DNA- and adenovirus-vectored malaria vaccine encoding blood-stage antigens AMA1 and MSP142 in a prime/boost heterologous immunization regimen partially Protects Aotus monkeys against blood-stage challenge. Clin Vaccine Immunol. 2017;24(4):e00539–16.
   PubMedGoogle Scholar
• Liu S, Wang S, Lu S. Using DNA immunization to elicit monoclonal antibodies in mice, rabbits, and humans. Hum Gene Ther. 2018;29:997–1003.
   Web of Science ®Google Scholar
• Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:100689.
   PubMedGoogle Scholar
• He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10:629–637.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tong X, Li Y, et al. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020;16:e1008796.
   Web of Science ®Google Scholar
• Chu R, Gerstein J, Wu H, et al. Development of rabbit monoclonal antibodies for quantitation of therapeutic human antibodies in preclinical non-human primate studies. Monoclon Antib Immunodiagn Immunother. 2020;39:175–183.
   Google Scholar
• Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–686.
   PubMed Web of Science ®Google Scholar
• Hamilton MA, Russo RC, Thurston RV. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol. 1977;11:6.
   Web of Science ®Google Scholar
• Lefranc MP, Giudicelli V, Duroux P, et al. IMGT(r), the international ImMunoGeneTics information system(R) 25 years on. Nucleic Acids Res. 2015;43:D413–D422.
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37:D1006–D1012.
   PubMed Web of Science ®Google Scholar
• Rambaut NL A, Pybus O, Barclay W, et al. (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological org https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.
   Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020. doi:https://doi.org/10.1101/2020.12.21.20248640:2020.12.21.20248640
   Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021. doi:https://doi.org/10.1016/j.cell.2021.03.013
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135.
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Coyle EM, Klenow L, et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020;12(550):eabc3539. doi:https://doi.org/10.1126/scitranslmed.abc3539
   Google Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27:622–625.
   PubMed Web of Science ®Google Scholar
• Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021. doi:https://doi.org/10.1038/s41591-021-01270-4
   Web of Science ®Google Scholar
• Huang B, Dai L, Wang H, et al. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. Lancet Microbe. 2021. doi:https://doi.org/10.1016/S2666-5247(21)00082-3
   Google Scholar
• Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021. doi:https://doi.org/10.1016/j.chom.2021.04.007
   Google Scholar